Intersite Variation of Estrogen Receptors in Human Breast Cancers and Response to Endocrine Therapy

Oncology ◽  
1992 ◽  
Vol 49 (2) ◽  
pp. 89-92 ◽  
Author(s):  
Yuichi lino ◽  
Noritaka Sugamata ◽  
Michio Maemura ◽  
Takeshi Takeo ◽  
Susumu Owada ◽  
...  
Keyword(s):  
Estrogen Receptors ◽  
Endocrine Therapy ◽  
Breast Cancers ◽  
Human Breast

Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

1995 ◽  
Vol 64 (4) ◽  
pp. 269-273 ◽  
Author(s):  
Julia M. W. Gee ◽  
Ian O. Ellis ◽  
John F. R. Robertson ◽  
Peter Willsher ◽  
Richard A. McClelland ◽  
...  
Keyword(s):  
Endocrine Therapy ◽  
Prognostic Markers ◽  
Immunocytochemical Localization ◽  
Breast Cancers ◽  
Human Breast ◽  
Fos Protein

scholarly journals The Role of Estrogen in the Development of Breast Cancer

2021 ◽  
Vol 7 (2) ◽  
pp. 231-241
Author(s):  
Nikki Aldi Massardi
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Tumor Growth ◽  
Endocrine Therapy ◽  
Breast Cancers ◽  
Mitogenic Effect ◽  
Human Breast ◽  
Clinically Significant ◽  
Circulating Levels

Breast cancer is a hormone-dependent disease that relies on the mitogenic effect ofestrogen to increase tumorigenesis and tumor growth. Clinically significant levels ofestrogen-α receptor (ERα) expression are seen in 80% of human breast cancers,whereas progesterone receptor is expressed in 55% of human breast cancers. Thesedata are one of the bases for the development of endocrine therapy. Endocrinetherapy is therapy that targets the pathway and synthesis of estrogen, by blocking itvia receptors, reducing circulating levels of estrogen, or suppressing estrogensynthesis in the tissues of women diagnosed with breast cancer.

scholarly journals INTER-SITE VARIATION OF ESTROGEN RECEPTORS AND EFFECT OF ENDOCRINE THERAPIES IN HUMAN BREAST CANCERS

1985 ◽  
Vol 35 (5) ◽  
pp. 477-480
Author(s):  
YUICHI IINO ◽  
KENNEI YAMAZAKI ◽  
HIROSHI ISHIKAWA ◽  
MASARU IZUO ◽  
HIROO TAKIKAWA
Keyword(s):  
Estrogen Receptors ◽  
Breast Cancers ◽  
Human Breast ◽  
Site Variation

Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers

1989 ◽  
Vol 32 (4) ◽  
pp. 485-492 ◽  
Author(s):  
Casper H. van Aswegen ◽  
Robert H. Purdy ◽  
James L. Wittliff
Keyword(s):  
Estrogen Receptors ◽  
Breast Cancers ◽  
Human Breast

Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

1994 ◽  
Vol 59 (5) ◽  
pp. 619-628 ◽  
Author(s):  
Julia M. W. Gee ◽  
John F. R. Robertson ◽  
Ian O. Ellis ◽  
Peter Willsher ◽  
Richard A. McClelland ◽  
...  
Keyword(s):  
Endocrine Therapy ◽  
Prognostic Markers ◽  
Immunocytochemical Localization ◽  
Breast Cancers ◽  
Human Breast

Content of estrogen receptors in human breast cancers

1973 ◽  
Vol 9 (5) ◽  
pp. 353-357 ◽  
Author(s):  
U. Spaeren ◽  
S. Olsnes ◽  
I. Brennhovd ◽  
J. Efskind ◽  
A. Pihl
Keyword(s):  
Estrogen Receptors ◽  
Breast Cancers ◽  
Human Breast

scholarly journals MRCKα Is Dispensable for Breast Cancer Development in the MMTV-PyMT Model

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 942
Author(s):  
Mei Qi Kwa ◽  
Rafael Brandao ◽  
Trong H. Phung ◽  
Jianfeng Ge ◽  
Giuseppe Scieri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression Signature ◽  
Genomic Analysis ◽  
Cancer Development ◽  
Breast Cancer Cell Lines ◽  
Normal Mammary Gland ◽  
Breast Cancers ◽  
Human Breast ◽  
Breast Cancer Development

MRCKα is a ubiquitously expressed serine/threonine kinase involved in cell contraction and F-actin turnover, which is highly amplified in human breast cancer and part of a gene expression signature for bad prognosis. Nothing is known about the in vivo function of MRCKα. To explore MRCKα function in development and in breast cancer, we generated mice lacking a functional MRCKα gene. Mice were born close to the Mendelian ratio and showed no obvious phenotype including a normal mammary gland formation. Assessing breast cancer development using the transgenic MMTV-PyMT mouse model, loss of MRCKα did not affect tumor onset, tumor growth and metastasis formation. Deleting MRCKα and its related family member MRCKβ in two triple-negative breast cancer cell lines resulted in reduced invasion of MDA-MB-231 cells, but did not affect migration of 4T1 cells. Further genomic analysis of human breast cancers revealed that MRCKα is frequently co-amplified with the oncogenes ARID4B and AKT3 which might contribute to the prognostic value of MRCKα expression. Collectively, these data suggest that MRCKα might be a prognostic marker for breast cancer, but probably of limited functional importance.

Sign in / Sign up

Export Citation Format

Share Document